

Open Access

POSTER PRESENTATION

Dual-targeting nanoparticles for reprogrammed T cell responses in the tumor microenvironment

Alyssa K Kosmides^{1*}, Jonathan Schneck²

From Society for Immunotherapy of Cancer 29th Annual Meeting National Harbor, MD, USA. 6-9 November 2014

One of the largest obstacles in cancer immunotherapy involves overcoming the immunosuppressive tumor microenvironment [1]. While many therapies are focused primarily on activating antigen-specific CD8+ T cells, the tumor microenvironment often expresses immunosuppressive cytokines and other immunoregulatory proteins such as checkpoint blockade molecules that diminish their effects [2]. Programmed death ligand 1 (PD-L1) is an inhibitory checkpoint molecule upregulated on many cancers, including melanoma, ovarian cancer, and renal cancer [3]. This can shield a tumor from immune attack by binding to its receptor, PD-1, on T cells. We have developed a nanoparticle platform that combines blockade of PD-L1 with the T cell co-stimulatory signal, anti-4-1BB. This dual targeting system redirects effector cells to recognize target cells while simultaneously blocking checkpoint inhibitors. Antagonistic anti-PD-L1 antibodies and agonistic anti-4-1BB antibodies are conjugated to the surface of biocompatible 50-100 nm iron dextran nanoparticles. The nanoparticles cause a 6-fold increase in IFN-y production by CD8+ T cells with an exhausted phenotype in the presence of tumor cells in vitro. Additionally, we have shown tumor suppression and a 30% decrease of PD-1 expression in tumor infiltrating lymphocytes in an in vivo B16 mouse melanoma model. This approach may not only reprogram local signaling within the tumor microenvironment, but also promote polyclonal cytotoxic T cell responses in the absence of defining the antigenic specificity of the infiltrating T cells.

Authors' details

¹Johns Hopkins University, Baltimore, MD, USA. ²Johns Hopkins School of Medicine, Department of Pathology, Institute for Cell Engineering, Baltimore, MD, USA.

¹Johns Hopkins University, Baltimore, MD, USA Full list of author information is available at the end of the article



References

- Rabinovich GA, Gabrilovich D, Sotomayor EM: Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007, 25:267-96.
- Freeman GJ, Sharpe AH, Kuchroo VK: Protect the killer: CTLs need defenses against the tumor. Nat Med 2002, 8:787-9.
- 3. Kamphorst AO, Ahmed R: Manipulating the PD-1 pathway to improve immunity. *Curr Opin Immunol* 2013, 1-8.

doi:10.1186/2051-1426-2-S3-P108

Cite this article as: Kosmides and Schneck: **Dual-targeting nanoparticles for reprogrammed T cell responses in the tumor microenvironment.** *Journal for ImmunoTherapy of Cancer* 2014 **2**(Suppl 3):P108.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

BioMed Central

Submit your manuscript at www.biomedcentral.com/submit



© 2014 Kosmides and Schneck; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.